Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Tg Therapeutics (TGTX) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Tg Therapeutics (TGTX) over the last 10 years, with Q3 2025 value amounting to 18.16%.

  • Tg Therapeutics' EBIT Margin rose 33400.0% to 18.16% in Q3 2025 from the same period last year, while for Sep 2025 it was 19.32%, marking a year-over-year increase of 195100.0%. This contributed to the annual value of 12.74% for FY2024, which is 39100.0% up from last year.
  • Per Tg Therapeutics' latest filing, its EBIT Margin stood at 18.16% for Q3 2025, which was up 33400.0% from 24.69% recorded in Q2 2025.
  • Over the past 5 years, Tg Therapeutics' EBIT Margin peaked at 69.22% during Q3 2023, and registered a low of 96923.75% during Q4 2022.
  • In the last 5 years, Tg Therapeutics' EBIT Margin had a median value of 277.93% in 2023 and averaged 8898.68%.
  • As far as peak fluctuations go, Tg Therapeutics' EBIT Margin soared by 2000000000bps in 2021, and later plummeted by -929191400bps in 2022.
  • Over the past 5 years, Tg Therapeutics' EBIT Margin (Quarter) stood at 4004.61% in 2021, then tumbled by -2320bps to 96923.75% in 2022, then surged by 100bps to 28.39% in 2023, then skyrocketed by 197bps to 27.68% in 2024, then tumbled by -34bps to 18.16% in 2025.
  • Its EBIT Margin was 18.16% in Q3 2025, compared to 24.69% in Q2 2025 and 7.13% in Q1 2025.